Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Bio Therapeutic Drugs
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
10/17DJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
08/24 Cyclicals boost European shares while Dixons Carphone plummets
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/10 Cyclicals and ex-divs send European shares to four-month low
07/31 France's Sanofi raises earnings forecast, pleased with eczema drug uptake
07/31DJSanofi 2Q Net Profit Down 10% at EUR1.04 Billion
07/27DJUNITED THERAPEUTICS : in Settlement Talks With Justice Department -- Update
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/29 UK and industrials prominent in Goldman strategists' M&A target reshuffle
06/20 Novartis eye drug works with fewer injections than rival
06/20 PAREXEL INTERNATIONAL : Pamplona Capital to take Parexel private for $4.5 billio..
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
06/09 ACTELION : Johnson & Johnson expects to complete Actelion purchase on June 16
06/09 ACTELION : Johnson & Johnson expects to complete of Actelion offer on June 16
06/02DJBluebird Bio stock jumps 7% after Maxim Group upgrades to buy -- MarketWatch
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/15 Thermo Fisher to buy Patheon for $5.2 billion to expand biopharma services
05/10DJMARKET SNAPSHOT : Nasdaq Closes At Record For 4th Straight Day As Dow Slips In F..
05/10DJMARKET SNAPSHOT : Stock Market Flat As Investors Digest Trump's Firing Of FBI's ..
05/10DJMARKET SNAPSHOT : Stock Market Falls After Trump's Firing Of FBI's Comey Raises ..
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
05/07 REGENERON PHARMACEUTICALS : shares poised for rebound - Barron's
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/18 European shares hit three-week lows amid jitters over British, French votes
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
04/04 European shares under pressure as autos, banks fall; oil stocks recover
Financials ($)
Sales 2017 25 966 M
EBIT 2017 15 929 M
Net income 2017 10 622 M
Debt 2017 13 436 M
Yield 2017 2,60%
P/E ratio 2017 10,13
P/E ratio 2018 11,93
EV / Sales 2017 4,60x
EV / Sales 2018 5,11x
Capitalization 106 B
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865
EXELIXIS, INC.84.17%7 985
BIOVERATIV INC0.00%6 515
BLUEBIRD BIO INC125.45%6 499
TESARO INC-13.44%6 307
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-0.41%5 647
NEUROCRINE BIOSCIENCES, INC.52.35%5 208
JUNO THERAPEUTICS INC130.24%4 881
HUALAN BIOLOGICAL ENGINEERING INC--.--%4 032
CLOVIS ONCOLOGY INC77.22%3 788
PEPTIDREAM INC-42.85%3 676
BEIGENE LTD (ADR)176.78%3 561
BIOCON LTD21.11%3 471
SAREPTA THERAPEUTICS INC87.46%3 341
AGIOS PHARMACEUTICALS INC66.76%3 254
AVEXIS INC112.07%3 194
BEIJING SL PHARMACEUTICAL CO LTD--.--%3 034